Introduction
============

Preeclampsia (PE) occurs during pregnancy, and seriously affects the health of pregnant women and fetuses. PE is the leading cause of increased maternal and fetal mortality worldwide ([@b1-ol-0-0-11721]). The incidence rate of PE is 9.4% in China and 7--12% abroad ([@b2-ol-0-0-11721]). The pathogenesis of PE is complicated and has not yet been fully elucidated. In addition, PE is associated with multiple risk factors. Previous studies have demonstrated that PE is associated with diabetes ([@b3-ol-0-0-11721]), obesity ([@b4-ol-0-0-11721]) and hypertension ([@b5-ol-0-0-11721]). It is difficult to prevent and treat PE as there are currently no effective drugs available. PE shares several pathophysiological mechanisms with cardiovascular diseases ([@b6-ol-0-0-11721]), which suggests that statins may be useful in prevention and early management of PE. Nevertheless, clinical evidence for the effectiveness of statins in the treatment of PE is mainly limited to animal models ([@b7-ol-0-0-11721]). It is generally recognized that the main clinical manifestations of PE are hypertension and proteinuria; however, the organs of pregnant women and fetuses may be impaired to varying degrees, and the majority of pregnant women do not exhibit clinical symptoms until 20 weeks of gestation ([@b8-ol-0-0-11721]). Accumulating evidence has confirmed that the occurrence and development of PE are associated with multiple genes and cellular pathways; no single factor can explain the pathogenesis and mechanism of PE ([@b9-ol-0-0-11721],[@b10-ol-0-0-11721]). Due to the high mortality rates in PE, revealing the causes, underlying molecular mechanisms, identifying molecular biomarkers and exploring effective medicine for early diagnosis, prevention and personalized treatment, are extremely important.

High-throughput sequencing and microarray technology play critical roles in revealing the pathogenesis of disease, and the structure and function of the genome ([@b11-ol-0-0-11721]). High-throughput analysis platforms combined with bioinformatics analysis can be used to discover key genes and search for effective drugs for therapy. Luo *et al* ([@b12-ol-0-0-11721]) identified 10 key genes in patients with PE compared with healthy donors. In addition, a study by Zhu *et al* ([@b13-ol-0-0-11721]) indicated that there were 11 upregulated microRNAs (miRNAs) and 23 downregulated miRNAs in patients with PE. However, the majority of previous studies focused on the significance of individual differentially expressed genes (DEGs) and did not investigate the association between the DEGs and PE as a whole. Therefore, previous studies may have missed biologically significant information about genes and their functions. In addition, few studies focused on screening of drugs for PE therapy.

In the present study, a gene expression profile dataset was obtained from the Gene Expression Omnibus (GEO) database ([@b14-ol-0-0-11721]). Gene set enrichment analysis (GSEA) was used to detect whether gene expression in defined functional groups is a common expression trend, which can link the microarray data with biological meaning ([@b15-ol-0-0-11721]). Furthermore, potential drugs for PE therapy were screened using connectivity map (CMAP) analysis. A number of studies have applied the CMAP database to disease treatment and drug development ([@b16-ol-0-0-11721]--[@b18-ol-0-0-11721]). The occurrence of PE is determined by changes in multiple genes. Therefore, the CMAP can indicate the structure of small molecule drugs for the treatment of PE. Recently, studies have focused on the role of gene expression and regulation in the development of PE ([@b19-ol-0-0-11721]--[@b23-ol-0-0-11721]). Therefore, the present study investigated novel key genes involved in the onset of PE. The aim of this study was to provide a novel perspective for further exploring the pathogenesis, treatment and prevention of PE.

Materials and methods
=====================

### Data source

Transcriptome expression profiles of normotensive pregnant woman and patients with PE were obtained from the microarray dataset GSE60438 ([@b24-ol-0-0-11721]) from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>). The dataset was based on the GPL6884 platform (Illumina HumanWG-6 v3.0 Gene Expression BeadChip; Illumina, Inc.), which contains probe information, including cDNAs, oligonucleotides and open reading frames. The dataset consists of 48 human samples, including 23 normotensive samples and 25 PE samples. The Bioconductor limma package (version 3.11) for R (version 4.0; <http://www.bioconductor.org/packages/release/bioc/html/limma.html>) was used to standardize, clean and convert the matrix data. Finally, the limma package was also used to identify DEGs ([@b25-ol-0-0-11721]). P\<0.05 and \|fold-change\| ≥1.2 were applied to screen DEGs in PE. The gplots package (version 3.0.3) was used to analyze the data and draw a heatmap plot (<https://github.com/talgalili/gplots>).

### Functional annotation of DEGs

Functional annotation of DEGs consisted of Gene Ontology (GO) analysis of biological process (BP) terms ([@b26-ol-0-0-11721]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis ([@b27-ol-0-0-11721]). GO and KEGG pathway databases were extensively used in analyzing the BPs and cellular signaling pathways that DEGs were involved in. The Database for Annotation Visualization and Integrated Discovery online tool (version 6.8; <http://david.ncifcrf.gov/>) was used to perform analysis of GO BP terms and KEGG pathway enrichment of DEGs in PE ([@b28-ol-0-0-11721]). Significantly enriched pathways and GO-BP terms with P\<0.01 were focused on in the present study.

### GSEA analysis of DEGs

GSEA is a tool for genome-wide expression profile data analysis that detects gene sets rather than individual gene expression changes. Therefore, GSEA could identify genes with small differences in expression and important functions, making the analysis more accurate and comprehensive ([@b15-ol-0-0-11721]). GSEA (version 2; <http://software.broadinstitute.org/gsea/index.jsp>) was used to determine whether an *a priori* defined set of genes enriched in GO BP terms and KEGG pathways shows significant differences between gene expression data of normotensive patients and patients with PE ([@b29-ol-0-0-11721]).

### Protein-protein interaction (PPI) network analysis

STRING (version 11.0; <http://string-db.org/>) is a database for searching interactions of known and predicted proteins, which was used to study the molecular mechanism of disease and investigate novel drug targets. In the present study, a PPI network of DEGs was extracted using the STRING tool. The PPI network was constructed using Cytoscape (version 3.4.0; <http://cytoscape.org/>). Only experimentally validated PPIs with a combined score \>0.4 were selected to construct the PPI network. Next, the hub genes associated with PE were identified in networks using CytoHubba (version 0.1; <http://www.cytoscape.org>) ([@b30-ol-0-0-11721]). CytoHubba provided a user-friendly interface to explore important nodes in biological networks. The Molecular Complex Detection (MCODE; version 1.4.2) ([@b31-ol-0-0-11721]) plugin in Cytoscape was then utilized to screen the top three modules in the PPI network. Parameters were set as follows: Degree cutoff, 2; node score cutoff, 0.2; k-core, 2; and maximum depth, 100.

### CMAP analysis

CMAP (<http://www.broadinstitute.org/cmap/>) is a database of small molecule drugs, gene expression and disease-related biological applications ([@b32-ol-0-0-11721]). CMAP contains the gene expression profiles of breast cancer MCF7 cells, prostate carcinoma PC3 cells and acute myeloid leukemia HL60 cells treated with different drugs. The CMAP database contains 1,309 small molecule drugs and \>7,000 gene expression profiles. Each small molecule drug treated different cells at different concentrations and time points. The gene expression profiles were analyzed to distinguish positive and negative regulatory gene groups. The score was based on the similarity of gene expression profiles between cells treated with small molecule drugs and disease gene expression profiles. Using CMAP analysis, gene expression profiles were compared to identify the drugs that were highly related to diseases, to deduce the main chemical structures of most drug molecules, and to summarize the possible mechanisms of drug molecules. Through CMAP analysis of DEGs in PE, small molecule drugs that could be used to treat PE were investigated. The cut-off value was defined as \|connectivity score\| \>0.7 to identify candidate small molecule drugs associated with PE.

### Extraction of tissue RNA and detection of expression of key genes by reverse transcription-quantitative (RT-q)PCR

A total of 38 placenta specimens were collected between March 2018 and December 2018, including 28 specimens from patients with PE and 10 from healthy pregnant women at the Department of Gynecology and Obstetrics, Affiliated Hospital of Jiangsu University (Zhenjiang, China). The diagnosis of PE was given according to the guidelines for the diagnosis and treatment of hypertensive disorders in pregnancy (2015) from the Group of Hypertensive Diseases in Pregnancy, the Society of Obstetrics and Gynecology of the Chinese Medical Association ([@b33-ol-0-0-11721]). The patients with PE did not suffer from any other disease. The age range of patients with PE and healthy controls was 20--45 years old. The researchers obtained verbal informed consent before collecting patient samples. Written informed consent was waived by the Ethics Committee of the Affiliated Hospital of Jiangsu University. The experiment was approved by the Ethics Committee of the Affiliated Hospital of Jiangsu University (approval no. 20170415). For evaluation of the expression of key genes in the placenta of patients and healthy women, tissue RNA was extracted using TRIzol^®^ (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed into cDNA using PrimeScript™ RT Master Mix (Takara Biotechnology Co., Ltd.) at 42°C for 30 min. qPCR was carried out using TB Green™ Fast qPCR mix on a CFX96™ Real-Time PCR Detection system (Bio-Rad Laboratories, Inc.). For the analysis of gene expression, quantification of relative mRNA levels was carried out using the 2^−ΔΔCq^ method ([@b34-ol-0-0-11721]). Values were normalized to endogenous β-actin expression. Each experiment was independently repeated three times. All primers used for RT-qPCR are listed in [Table I](#tI-ol-0-0-11721){ref-type="table"}. The thermocycling conditions were as follows: 95°C for 30 sec, followed by 40 cycles of 95°C for 5 sec and 60°C for 30 sec.

### Statistical analysis

In this experiment, the expression of genes in patients with PE and healthy controls of the GSE60438 dataset were analyzed with unpaired Student\'s t-test using the limma package for R. GO and KEGG pathway analyses were compared using Fisher\'s exact test. The false discovery rate was controlled within the appropriate range using the Benjamini-Hochberg method. Differences in the mRNA expression of proteasome 26S subunit, non-ATPase 14 (PSMD14), ubiquinol-cytochrome *c* reductase core protein 2 (UQCRC2) and prostaglandin E synthase 3 (PTGES3) between PE and healthy controls were compared using unpaired Student\'s t-test. Data were presented as mean ± SD. P\<0.05 was considered to indicate a statistically significant difference. The software used for analysis was GraphPad Prism 7 (GraphPad Software, Inc.).

Results
=======

### Identification of DEGs involved in PE

By performing data normalization and comparison, 441 DEGs were identified in PE based on the cut-off values (P\<0.05 and \|fold-change\| ≥1.2). A volcano plot of DEGs could significantly discriminate between patients with PE and normotensive pregnant woman ([Fig. 1](#f1-ol-0-0-11721){ref-type="fig"}). A heatmap plot showed the clustering of DEGs in PE and normotensive pregnant woman ([Fig. 2](#f2-ol-0-0-11721){ref-type="fig"}).

### GO BP and KEGG pathway enrichment analysis of the DEGs

The top seven KEGG pathways enriched with DEGs in PE are presented in [Fig. 3A](#f3-ol-0-0-11721){ref-type="fig"}. The DEGs were enriched in 'circadian rhythm'. BP terms that were enriched with DEGs were 'protein stabilization', 'positive regulation of telomere maintenance via telomerase,' 'circadian regulation of gene expression' and 'circadian rhythm' ([Fig. 3B](#f3-ol-0-0-11721){ref-type="fig"}).

### GSEA in PE

In GO BP analysis of the dataset, 1,706 signaling pathways were upregulated. There were 57 signaling pathways with P\<0.05. Of these, four had P\<0.01. In KEGG pathway analysis of the dataset, 96 signaling pathways were upregulated. Of these, one had P\<0.01 ([Fig. 4](#f4-ol-0-0-11721){ref-type="fig"}). KEGG results revealed that DEGs were significantly enriched in 'fatty acid metabolism'. GO results revealed that DEGs were enriched in 'DNA damage response detection of DNA damage', 'regulation of DNA repair', 'positive regulation of small GTPase mediated signal transduction', 'endothelial cell development', 'ERBB2 signaling pathway', 'positive regulation of cytokinesis' and 'cellular response to estradiol stimulus'.

### Identification of key genes of PE

The PPI network presented 590 experimentally validated interactions with a combined score \>0.4. In the present study, the top five genes with higher degrees were screened as hub genes in the PPI network using CytoHubba, including PSMD14, PTGES3, UQCRC2, small ubiquitin like modifier 2 and actin-related protein 3 ([Fig. 5](#f5-ol-0-0-11721){ref-type="fig"}). On the basis of the degree of importance, the three most significant modules were screened from the PPI network using MCODE ([Fig. 6A, C and E](#f6-ol-0-0-11721){ref-type="fig"}). The KEGG pathway enrichment analysis demonstrated that the most significant modules were primarily associated with 'circadian rhythm', 'glycolysis/gluconeogenesis', 'carbon metabolism' and 'neuroactive ligand-receptor interaction' ([Fig. 6B, D and F](#f6-ol-0-0-11721){ref-type="fig"}).

### CMAP analysis of the DEGs

The gene expression profiles of MCF7 breast cancer cells, PC3 prostate carcinoma cells and HL60 acute myeloid leukemia cells treated with drugs were divided into positive and negative regulatory gene groups. After eliminating the invalid probes (\|connectivity score\| \<0.7), 169 positive regulatory genes and 253 negative regulatory genes were identified. Additionally, drug predictive results similar to and opposite to PE in gene expression after drug treatment were obtained. According to drug prediction, 20 drugs produced similar gene expression patterns to PE. In [Table II](#tII-ol-0-0-11721){ref-type="table"}, drugs that may aggravate PE are presented. There were also 20 antipsychotic drugs, hypotensor and diuretics identified that may induce gene expression contrary to PE and may have improved effects on the treatment of PE ([Table III](#tIII-ol-0-0-11721){ref-type="table"}). Excluding prohibited medicines for pregnant women, furosemide and droperidol were selected based on higher negative scores. The molecular structures and running sums of furosemide and droperidol are shown in [Fig. 7](#f7-ol-0-0-11721){ref-type="fig"}. The running sum was based on the genomic expression profile of a drug, with which all the CMAP genomic expression profiles were compared. Finally, the drugs with the highest score of positive association (closest to +1) were considered to be potentially associated with the reference drug at the downstream gene regulation and clinical drug response levels.

### Verification of key genes in PE using RT-qPCR

A total of 38 placenta specimens were analyzed, 28 placenta specimens from patients with PE and 10 placenta specimens from healthy pregnant women, to confirm the results of the bioinformatics screening. The primer specificity and the optimal annealing temperatures for five pairs of primers were used for RT-qPCR ([Table I](#tI-ol-0-0-11721){ref-type="table"}). The mRNA expression of five genes were detected by RT-qPCR. The expression levels of PSMD14 and UQCRC2 were confirmed to be lower in the placenta of patients with PE compared with normotensive pregnant woman, while the expression levels of PTGES3 were higher in placentas of patients with PE compared with normotensive pregnant woman ([Fig. 8](#f8-ol-0-0-11721){ref-type="fig"}). The expression levels of ACTR3 and SUMO2 in the placenta of patients with PE presented no marked difference compared with normotensive pregnant women (data not shown). These findings indicated that the DEGs may be associated with the pathogenesis of PE.

Discussion
==========

PE is a multi-organ disease characterized by hypertension and proteinuria during pregnancy, which is one of the main causes of morbidity and mortality of pregnant women and perinatal infants. At present, the pathological mechanism of PE has not been elucidated. However, studies have indicated that the symptoms and signs of PE are caused by multiple factors, mechanisms and pathways.

Based on GO and KEGG analysis in the current study, a significant portion of DEGs were enriched in the circadian rhythm pathway. However, there are a limited number of studies on the association between alterations of the circadian rhythm and PE ([@b35-ol-0-0-11721]--[@b37-ol-0-0-11721]). The circadian rhythm of blood pressure has been explored in relation to the severity and progression of PE ([@b38-ol-0-0-11721]). Van den Berg *et al* ([@b39-ol-0-0-11721]) also indicated that the DNA methylation status of circadian clock and clock-controlled genes in placental tissue was different between patients with PE and healthy controls.

The KEGG result of GSEA in the current study suggested that DEGs may affect the progression of PE via the fatty acid metabolism pathway. Increased blood lipids and free fatty acids, caused by abnormal lipid and fatty acid metabolism, could enhance oxidative stress, inflammation, endothelial dysfunction and promote the occurrence of PE ([@b40-ol-0-0-11721]). The GO results of GSEA in the present study indicated that the incidence of PE was related to 'DNA damage response detection of DNA damage', 'regulation of DNA repair' and 'endothelial cell development', which is closely related to oxidative stress. Small artery spasms, low perfusion of organs and tissue hypoxia during PE have been reported to lead to excessive production of oxygen free radicals, which can result in protein oxidation, DNA mutation and breakage, and endothelial cell damage ([@b41-ol-0-0-11721]--[@b44-ol-0-0-11721]). According to the results of the present study, positive regulation of GTPase-mediated signal transduction may serve a key role in the occurrence of PE. The Rho family of GTPases are small molecule guanosine-binding proteins. Activation of the Rho/Rho-associated coiled-coil containing protein kinase (ROCK) pathway can lead to injury of vascular endothelial cells, small vessel spasms and eventually PE symptoms ([@b45-ol-0-0-11721]). In addition, according to the present study the occurrence of PE may be associated with the Erb-B2 receptor tyrosine kinase 2 signaling pathway, positive regulation of cytokines and cellular response to estradiol stimulus.

In the present study, CMAP analysis revealed the association between PE and certain drugs. Furosemide and droperidol induced gene expression that was contrary to PE. Furosemide is a diuretic that is used to treat eclampsia complicated with intracranial hypertension ([@b46-ol-0-0-11721]). Droperidol has strong antipsychotic effects that are mainly related to its antagonism to dopamine receptors; it promotes the transformation of dopamine in the brain ([@b47-ol-0-0-11721]). These two drugs may prove to have therapeutic benefits in preventing the development or progression of PE.

Through the construction of a PPI network, five hub genes with higher degrees were identified. However, only PSMD14, PTGES3 and UQCRC2 were verified to be significantly different between placenta samples from patients with PE and normotensive pregnant woman. PSMD14 is one of the 19 essential subunits of a completely assembled 19S proteasome complex ([@b48-ol-0-0-11721]). In the current study, the expression of PSMD14 was significantly lower in the placenta of patients with PE compared with normotensive pregnant woman. Therefore, the activity and function of the proteasome may be decreased in patients with PE. A previous study demonstrated that proteasomal activity and function was decreased by \~30% in PE placenta ([@b49-ol-0-0-11721]). Proteasomes degrade oxidative stress proteins that destroy cells and tissues. Previous studies have shown that the oxidative stress-associated proteins were increased by \~30% in the placenta of patients with PE compared with the placenta of healthy pregnant women ([@b50-ol-0-0-11721]--[@b52-ol-0-0-11721]). Oxidative stress-associated proteins mainly refer to the products of oxidative stress, such as damaged DNA bases, protein oxidation products and lipid peroxidation products. These findings suggested that decreased proteasomal activity due to reduced expression of PSMD14 could lead to the accumulation of oxidatively damaged proteins in PE.

UQCRC2, a member of the peptidase M16 family, is an indispensable component of mitochondrial complex III, which is a part of the mitochondrial respiratory chain ([@b53-ol-0-0-11721],[@b54-ol-0-0-11721]). In the present study, the expression of UQCRC2 was lower in placenta samples from patients with PE compared with in healthy placenta samples. According to a previous study, UQCRC2 may be involved in the production of intracellular reactive oxygen species (ROS) and oxidative stress ([@b53-ol-0-0-11721]). In addition, decreased expression of UQCRC2 led to increased cellular ROS level ([@b53-ol-0-0-11721]). PTGES3 is a molecular chaperone located in genomic response elements that may break down transcriptional regulatory complexes and destroy receptor-mediated transcriptional activation ([@b55-ol-0-0-11721]). PTGES3 is essential for the normal physiological function of the glucocorticoid receptor and other steroid receptors. Disordered steroid synthesis and metabolism is an important factor leading to PE ([@b56-ol-0-0-11721]). PSMD14, PTGES3 and UQCRC2 are all involved in oxidative stress, carcinoma, and steroid synthesis and metabolism ([@b57-ol-0-0-11721]--[@b59-ol-0-0-11721]). The changes in mRNA expression of PSMD14, PTGES3 and UQCRC2 detected in the present study suggested that carcinoma and oxidative stress signals may be involved in the occurrence and development of PE. In the current study, patients with PE exhibited decreased expression of PSMD14 and UQCRC2. Previous studies have shown that PSMD14 and UQCRC2 are involved in oxidative stress signals; decreased expression of PSMD14 and UQCRC2 is associated with oxidative damage to vascular endothelial cells ([@b49-ol-0-0-11721],[@b53-ol-0-0-11721]). In the present study, PTGES3 exhibited increased expression in patients with PE. It has been reported that PTGES3 may be involved in steroid synthesis and metabolism signals; abnormal expression of PTGES3 can lead to disordered steroid synthesis and metabolism, and thus to the development of PE ([@b56-ol-0-0-11721]). In addition, it has been reported that UQCRC2 is involved in carcinoma cell signaling; it is of note that carcinoma signaling pathways, such as Notch, RhoA/ROCK and NF-κB, are also related to PE ([@b60-ol-0-0-11721]--[@b62-ol-0-0-11721]). Abnormal expression of UQCRC2 can result in disorders of carcinoma signaling and also possibly the occurrence of PE.

In conclusion, the pathogenesis of PE has been found to involve multiple cellular signaling pathways and BPs. The present study indicated that furosemide and droperidol may have beneficial effects as PE treatments. Furthermore, the downregulation of PSMD14 and UQCRC2 expression may induce increased oxidative stress in PE, whereas the upregulation of PTGES3 expression may lead to disordered steroid synthesis and metabolism, which could participate in the development of PE. Therefore, these three hub genes may be biomarkers or therapeutic targets in PE.
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![Functional enrichment analyses of the differentially expressed genes. (A) Results of Kyoto Encyclopedia of Genes and Genomes pathway analysis. (B) Analysis results of GO BP. GO, Gene Ontology; BP, biological process.](ol-20-02-1585-g02){#f3-ol-0-0-11721}

![Significant enrichment plots in preeclampsia using GSEA. GSEA results showed enrichent in (A) 'Fatty acid metabolism', (B) 'DNA damage response detection of DNA damage', (C) 'Regulation of DNA repair', (D) 'Positive regulation of small GTPase mediated signal transduction', (E) 'Endothelial cell development', (F) 'ERBB2 signaling pathway', (G) 'Positive regulation of cytokinesis' and (H) 'Cellular response to estradiol stimulus'. GSEA, gene set enrichment analysis; GO, Gene Ontology.](ol-20-02-1585-g03){#f4-ol-0-0-11721}

![Protein-protein interaction network of differentially expressed genes in placenta samples between patients with preeclampsia and healthy pregnant women. Red dots are indicative of hub genes and bule dots are indicative of non-hub genes.](ol-20-02-1585-g04){#f5-ol-0-0-11721}
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###### 

Primer sequences of hub genes and the annealing temperature used for reverse transcription-quantitative PCR.

  Primer    Primer sequence (5′-3′)    Annealing temperature (°C)
  --------- -------------------------- ----------------------------
  PSMD14    F: CAGATGCTCCTGCAGTGGAC    61.5
            R: AACAACCATCTCCGGCCTTC    
  PTGES3    F: ACGTTCATTCTCCGTCCTCG    56.7
            R: AAGCAGGCTGCATTGTGAAC    
  UQCRC2    F: ACGCAAAAAGCAGTGACGTA    60.3
            R: CCGGCTCTGGTTAGTAGCTT    
  SUMO2     F: GCGGACCTGGTACCTCTTTT    53.6
            R: TCCAACTGTGCAGGTGTGTC    
  ACTR3     F: TTCTTGCTACTGCTTCGGCTT   61.1
            R: AGCTTGATCACCCACTTTTGC   
  β-actin   F: AGCGAGCATCCCCCAAAGTT    56
            R: GGGCACGAAGGCTCATCATT    

F, forward; R, reverse; PSMD14, proteasome 26S subunit, non-ATPase 14; PTGES3, prostaglandin E synthase 3; UQCRC2, ubiquinol- cytochrome *c* reductase core protein 2; SUMO2, small ubiquitin like modifier 2; ACTR3, actin-related protein 3.

###### 

Drug prediction results similar to preeclampsia in gene expression after drug treatment.

  Rank   Batch   CMAP name          Dose (µM)   Cell   Score   Up      Down     Instance_ID
  ------ ------- ------------------ ----------- ------ ------- ------- -------- -------------
  1      694     Nystatin           4           MCF7   1       0.236   −0.254   4807
  2      1,068   0198306-0000       10          MCF7   0.922   0.193   −0.259   7064
  3      743     Nocodazole         13          MCF7   0.919   0.212   −0.239   6793
  4      693     R-atenolol         15          PC3    0.894   0.17    −0.268   4259
  5      695     Cyclopenthiazide   11          MCF7   0.879   0.183   −0.248   4813
  6      704     Sulpiride          12          PC3    0.865   0.143   −0.281   4566
  7      756     Nomegestrol        11          MCF7   0.846   0.196   −0.219   6525
  8      745     Dizocilpine        12          MCF7   0.844   0.153   −0.261   6223
  9      1,082   Irinotecan         100         MCF7   0.843   0.191   −0.222   7498
  10     744     Clobetasol         9           MCF7   0.84    0.198   −0.214   6835
  11     702     Eucatropine        12          PC3    0.838   0.171   −0.24    4316
  12     693     Picrotoxinin       14          PC3    0.836   0.182   −0.229   4260
  13     695     Simvastatin        10          MCF7   0.828   0.158   −0.248   4828
  14     701     Phenformin         17          PC3    0.823   0.19    −0.213   4283
  15     702     Promazine          12          PC3    0.814   0.157   −0.243   4308
  16     694     Benperidol         10          MCF7   0.813   0.13    −0.269   4781
  17     718     Allantoin          25          PC3    0.807   0.175   −0.221   5052
  18     693     Sulfaguanidine     19          PC3    0.806   0.213   −0.183   4257
  19     694     Mestranol          13          MCF7   0.801   0.126   −0.267   4792
  20     756     Alfaxalone         12          MCF7   0.801   0.172   −0.22    6514

###### 

Drug prediction results opposite to preeclampsia in gene expression after drug treatment.

  Rank   Batch   CMAP name             Dose (µM)   Cell   Score    Up       Down    Instance_ID
  ------ ------- --------------------- ----------- ------ -------- -------- ------- -------------
  1      731     Tetrahydroalstonine   11          PC3    −0.763   −0.135   0.246   5728
  2      694     Zardaverine           15          MCF7   −0.768   −0.137   0.246   4793
  3      692     Idoxuridine           11          PC3    −0.769   −0.168   0.216   4200
  4      1,059   PF-00562151-00        10          MCF7   −0.773   −0.154   0.232   6912
  5      694     Pyrimethamine         16          MCF7   −0.781   −0.14    0.249   4779
  6      692     Epitiostanol          13          PC3    −0.782   −0.141   0.248   4204
  7      706     Prestwick-984         9           MCF7   −0.782   −0.174   0.216   4948
  8      706     Retrorsine            11          MCF7   −0.783   −0.175   0.215   4946
  9      694     Gabexate              10          MCF7   −0.784   −0.176   0.215   4804
  10     692     Naftopidil            9           PC3    −0.788   −0.165   0.228   4193
  11     1,059   SB-202190             1           MCF7   −0.791   −0.145   0.25    6909
  12     630     Droperidol            11          HL60   −0.791   −0.221   0.173   1290
  13     690     Boldine               12          MCF7   −0.807   −0.165   0.238   4122
  14     694     Zalcitabine           19          MCF7   −0.817   −0.161   0.247   4799
  15     677     Iopanoic acid         7           MCF7   −0.818   −0.174   0.234   3527
  16     692     Molindone             13          PC3    −0.838   −0.192   0.226   4199
  17     693     Amprolium             13          PC3    −0.855   −0.193   0.233   4241
  18     702     0317956-0000          10          PC3    −0.859   −0.222   0.206   4331
  19     728     Furosemide            12          PC3    −0.86    −0.162   0.267   4503
  20     694     Meptazinol            15          MCF7   −1       −0.245   0.254   4774

[^1]: Contributed equally
